Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D

Monte Rosa Therapeutics

06/08/2026 12:25

Overview
US biotech firm's Q2 collaboration revenue fell sharply yr/yr 
Company posted wider Q2 net loss as operating expenses increased
Cash and securities of $626 mln expected to support operations into 2029

Outlook
Monte Rosa expects to initiate multiple MRT-8102 Phase 2 studies in H2 2026 through H1 2027
Readout of MRT-8102 GFORCE-1 study in elevated CVD risk subjects anticipated in H2 2026
Company expects Novartis to initiate multiple MRT-6160 Phase 2 studies in immune-mediated diseases in 2026

Result Drivers
R&D SPENDING - Higher Q2 R&D expenses driven by increased investment in MRT-8102 and other development programs

Company press release: ID:nGNX68RcLn

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$8.97 mln
 
Q2 Net Loss
 
$43.40 mln
 
Q2 Operating Expenses
 
$58.10 mln
 
Q2 Operating Income
 
-$49.13 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Monte Rosa Therapeutics, Inc. is $29.00, about 85.8% above its August 5 closing price of $15.61

Reuters Recommended Reads
Aug 5 - Context Therapeutics Q2 net loss widens on higher R&D costs
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses
Aug 5 - Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)